Program

HomeProgram ▶ Non-CME Symposia
Non-CME Symposia

Sunday, May 20, 2018
Tuesday, May 22, 2018

Sunday, May 20, 2018

Hilton San Diego Bayfront

Indigo Ballroom A/E (Indigo Level, Level 2)

06:30 PM - 09:30 PM


Consider the Risk: A Case-based Look at Risk Assessment in PAH Management

Management strategies of pulmonary arterial hypertension (PAH) continue to evolve. Currently, management guidelines recommend risk assessment as a critical component to drive treatment decision-making and comprehensive care for patients with PAH. This interactive, case-based symposium will feature a panel of experts who will discuss the importance of risk assessment in PAH. Dinner will be provided. Dinner will not be provided to physicians and other healthcare professionals licensed in Vermont or other states where gifts and meals are prohibited. A non-CME educational program sponsored by Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceuticals Company of Johnson & Johnson, open to all ATS 2018 International Conference attendees.

Speakers: Vallerie McLaughlin MD University of Michigan ; Nick H. Kim MD University of California, San Diego; Lana Melendres-Groves MD University of New Mexico School of Medicine

Company: Actelion Pharmaceuticals US, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson


Indigo Ballroom D/H (Indigo Level, Level 2)

06:30 PM - 09:30 PM


Idiopathic Pulmonary Fibrosis: From Presentation to Patient Experience

This educational symposium will feature a patient mentor who will share their journey of living with IPF. Our distinguished faculty, who actively diagnose and treat patients with IPF, will provide clinical context for the patient story using a case-based slide format to present background information on IPF and relevant information regarding the diagnostic process. The program will conclude with a review of the most up-to-date data supporting the efficacy and safety of OFEV® (nintedanib) for the treatment of IPF.

Speakers: Paul W. Noble MD Cedars-Sinai Medical Center; Jeffrey James Swigris DO, MS National Jewish Health

Company: Boehringer Ingelheim Pharmaceuticals, Inc.


Sapphire Ballroom A/B/E/F (Sapphire Level, Level 4)

06:30 PM - 09:30 PM


Clinical Issues in Severe Asthma: Debates and Discussions About Personalizing Patient Management

Please join us for an engaging and illuminating Clinical Issues™ symposium focused on evolving management strategies for severe cases of asthma. A faculty panel comprising 3 well-known experts in asthma research will review key diagnostic criteria; biomarkers and comorbidities that help elucidate severe phenotypes and shape therapeutic choices; and the mechanistic and clinical profiles associated with current and emerging biologic asthma therapies. A brief didactic introduction to each topic will set the stage for animated exchanges of faculty views, allowing each presenter to highlight actionable recommendations founded in the growing evidence base but filtered through the lens of the expert’s extensive clinical experience.

Speakers: Reynold A. Panettieri, Jr MD University of Pennsylvania; Michael E. Wechsler MD, MMSc National Jewish Health; Sally E. Wenzel MD Pulmonary, Allergy and Critical Care Medicine

Company: Supported by an independent educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.


Sapphire Ballroom I/J/M/N (Sapphire Level, Level 4)

06:30 PM - 09:30 PM


Recent evidence in the treatment of COPD: an interactive symposium (Open to International attendees only)

The GOLD Report emphasises that treatment goals should be to alleviate symptoms, reduce exacerbations and outlines treatment pathways; however, as with all disease management guidelines there are often evidence gaps in support these recommendations. Recently, new evidence has emerged that may provide greater clarity about which therapies are best suited to achieve GOLDs treatment goals and ensure that each patient obtains the right treatment. This Scientific Symposium will focus on a review of recent evidence, how it guides appropriate treatment, where evidence gaps still exist and what future research is needed. The program will include a panel of experts and elements for audience participation to engage in the discussion and debate.

Speakers: Paul Jones PhD, FRCP, FERS Global Respiratory Franchise, GlaxoSmithKline, London, UK; Gerard Criner MD Temple University Hospital, Philadelphia, PA; Fernando Martinez MD, MS Weill Cornell Medicine, New York, NY; Paul Jones PhD, FRCP, FERS Global Respiratory Franchise, GlaxoSmithKline, London, UK; Dave Singh MD Institution: University Of Manchester, Manchester, UK; Paul Jones PhD, FRCP, FERS Global Respiratory Franchise, GlaxoSmithKline, London, UK; Neil Barnes MB, BS, FRCP Global Respiratory Franchise, GlaxoSmithKline, London, UK; Paul Jones PhD, FRCP, FERS Global Respiratory Franchise, GlaxoSmithKline, London, UK

Company: GSK


Manchester Grand Hyatt San Diego

Grand Hall A (Lobby Level)

06:30 PM - 09:30 PM


New Therapies, New Opportunities and New Challenges in Managing NTM

Wrap up your ATS experience with a pre-activity social event. Relax and challenge your colleagues in a nontuberculous mycobacterial (NTM) trivia contest, and enjoy cocktail hour before we begin. Then join Drs. David Griffith, Kevin Winthrop, and Ted Marras as they describe patients at high risk for NTM lung infection and apply the latest emerging therapies to clinical cases. Managing NTM lung disease has been called a “lengthy, complicated, and time-consuming process.” Participants will use iPads to interact with the faculty and engage in clinical decision-making. Register at http://pilotforipf.org/ntm18

Speakers: David Griffith MD University of Texas Health Science Center; Ted Marras MD, FRCPC, M.Sc. University of Toronto; Kevin Winthrop MD, MPH Oregon Health & Science University

Company: This non-CME educational program is sponsored by The France Foundation, and supported by an independent educational grant from Insmed, Incorporated.


Grand Hall D (Lobby Level)

06:30 PM - 09:30 PM


Real World Impact in IPF: How to Make System Level Changes

IPF experts will share real-world examples of successful initiatives that have impacted clinical care of patients with IPF. The session will demonstrate how learners can make sustainable systems-based changes in their own practice that have potential to improve early diagnosis and the management of IPF. Education isn’t confined to this session—interested learners will be offered a series of virtual mentorships with faculty to discuss potential efforts with their own institutions. Our program will utilize iPads to engage the learners and will conclude with a “meet the faculty” session where learners can speak with faculty one-on-one. Register now at http://pilotforipf.org/ipf18

Speakers: Evans R. Fernández Pérez MD, MS National Jewish Health; Amy L. Olson MD, MSPH National Jewish Health; Meena Kalluri MD University of Alberta

Company: This non-CME educational program is sponsored by The France Foundation, and supported by independent educational grants from Boehringer Ingelheim Pharmaceuticals, Inc., and Genentech.


Harbor Ballroom G-I (Second Level, Harbor Tower)

06:30 PM - 09:30 PM


Redefining the Approach to Asthma and COPD: A New Perspective on Mechanisms of Disease

You are cordially invited to an AstraZeneca sponsored non-CME dinner program on emerging mechanisms of disease in asthma and COPD. This faculty led symposium will examine asthma and COPD from the phenotype/endotype perspective to demonstrate the importance of relating observable characteristics to mechanisms of disease. This presentation will include a discussion of our current understanding of eosinophils and other immunologic pathways and their association with disease severity, lung function decline and negative outcomes. The program will conclude with a prospective look at the evolving goals of therapy and the questions that must be addressed to target mechanisms of disease toward the goal of delivering patient centric care.

Speakers: Bartolome R. Celli MD Harvard Medical School Boston, MA; Nicola Hanania MD, MS Baylor College of Medicine Houston, TX; Jill Ohar MD Wake Forest Baptist School of Medicine Winston-Salem, NC; Sanjay Sethi MD University of Buffalo, NY

Company: AstraZeneca


Seaport Ballroom G-H (Second Level, Seaport Tower)

06:30 PM - 09:30 PM


Optiflow™ Nasal High Flow Evidence and Equipoise

Delegates will learn and hear from three internationally respected researchers who will deliver clinically focused yet practical presentations on Nasal High Flow (NHF) therapy with F&P Optiflow™and F&P AIRVO™. At the end of this symposium delegates will be able to: > Identify the current evidence for Nasal High Flow (NHF) therapy > Evaluate the emerging and clinically significant applications for NHF therapy > Direct evidence-based process change regarding the use of NHF therapy

Speakers: JEAN-PIERRE FRAT MD Centre Hospitalier Universitaire de Poitiers; NICHOLAS S. HILL MD Tufts Medical Centre, Boston; GIACOMO GRASSELLI MD Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan

Company: Fisher & Paykel Healthcare


San Diego Marriott Marquis & Marina

Marina Ballroom D-E (South Tower, Third Floor)

06:30 PM - 09:30 PM


Emerging European PAH Registry Data: Risk Assessment With the Urgency to Treat

The progressive nature of PAH, and the poor prognosis it carries for most patients, provides clinical rationale for an aggressive approach to disease management. Recent real-world data from three European PAH registries support the prognostic utility of risk stratification outlined in the 2015 ESC/ERS treatment guidelines. These results emphasize that disease stabilization may not be sufficient for all patients. Experts in PAH treatment will discuss current risk assessment strategies and their implementation in clinical practice to support a goal-oriented approach in the treatment of PAH.

Speakers: Ronald Oudiz MD, FACP, FACC, FCCP LA Biomedical Institute at Harbor-UCLA Medical Center; Harrison "Hap" Farber MD Boston Medical Center; Ioana Preston MD Tufts Medical Center; Susie McDevitt RN, MSN, ACNP University of Michigan Health System

Company: United Therapeutics


Marina Ballroom F-G (South Tower, Third Floor)

06:30 PM - 09:30 PM


How Are We Diagnosing and Managing Our Patients With IPF? An Expert-Guided Discussion

Join us for a collaborative discussion with a multidisciplinary team of renowned interstitial lung disease (ILD) experts to investigate the key barriers and benefits to timely diagnosis and management of patients with IPF.

Speakers: Steven D. Nathan MD Inova Fairfax Hospital; Shyam Subramanian MD Sutter Gould Medical Foundation; Alison G. Wilcox MD University of Southern California

Company: Genentech, A Member of the Roche Group


Tuesday, May 22, 2018

Hilton San Diego Bayfront

Indigo Ballroom A/E (Indigo Level, Level 2)

06:30 PM - 09:30 PM


Uncovering a Genetic Cause of COPD: Alpha1-antitrypsin

Alpha-1 Antitrypsin Deficiency (alpha-1) is a genetic cause of COPD that is severely underdiagnosed, with as many as 90% of the individuals living with the condition undetected. Learn about how this condition presents, which patients may be at risk, and genetic testing used to diagnose. You’ll also gain insights into the patient journey from an experienced patient and advocate.

Speakers: Dr. Kamyar Afshar Pulmonologist UC San Diego; Len Geiger Alpha-1 Patient Advocate

Company: Grifols USA, LLC.


Indigo Ballroom C/G (Indigo Level, Level 2)

06:30 PM - 09:30 PM


Win the Room! Updates in Interstitial Lung Disease: Making Strides in Accurate Diagnosis and Optimized Treatment Register online at: peerview.com/ILD18

Optimal management of patients with ILD, including IPF, begins with accurate diagnosis and relies on safe and effective incorporation of newly approved and investigational therapies into individualized patient treatment paradigms. In this program, audience-response devices will allow the room to be segmented into teams competing via score-based questions. The game will be driven by faculty presentations focused on distinguishing IPF and other ILDs via distinct radiographic patterns and pathologic features, late-breaking clinical data on approved and emerging regimens, and strategies for applying evidence-based recommendations to optimize IPF management. The team with the highest point total will be crowned as having “Won the Room.”

Speakers: Lisa H. Lancaster MD Vanderbilt University Medical Center; Marilyn K. Glassberg MD University of Miami Miller School of Medicine; Sylvester Comprehensive Cancer Center ; Steven D. Nathan MD Inova Fairfax Hospital; Virginia Commonwealth University-Inova Fairfax Campus

Company: This non-CME educational program is sponsored by PVI, PeerView Institute for Medical Education, and supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.


Indigo Ballroom D/H (Indigo Level, Level 2)

06:30 PM - 09:30 PM


Compete and Win! Pulmonary Hypertension at the Crossroads of Current Clinical Challenges and Novel Therapeutic Strategies Register online at: peerview.com/PH18

​Familiarity with key diagnostic criteria, the ability to differentiate between various types of PH, and understanding how recent clinical trial data impacts the application of treatment options are vital components of PAH and CTEPH management. Utilizing a fun and interactive game-based teaching approach, expert-led presentations on diagnosis, differentiation and treatment will be enhanced by related assessment questions which, when answered via audience-response devices, will record an ongoing score and associated leaderboard. Each participant will be part of a larger team and the group with the top score at the end of the session will be hailed as victors along with enhanced ability to manage of patients with PAH and CTEPH.

Speakers: Nick H. Kim MD University of California San Diego; Richard N. Channick MD Massachusetts General Hospital; Harvard Medical School; Vallerie V. McLaughlin MD University of Michigan

Company: This non-CME educational program is sponsored by PVI, PeerView Institute for Medical Education, and supported through an educational grant from Bayer US.


Sapphire Ballroom A/B/E/F (Sapphire Level, Level 4)

06:30 PM - 09:30 PM


Type 2 Inflammation in Asthma: Defining Features and Lung Function

Our moderator and expert-panel will lead an interactive discussion of three asthma patient case studies highlighting the importance of Type 2 inflammation in asthma control, severity and lung function. Using an ARS response system, attendees will help evaluate the significance of patient clinical features and Type 2 biomarkers. Discussion throughout will focus on how clinical features, biomarkers and lung function results (eg. FEV1) together may inform patient severity, control and exacerbation risk. We will also discuss how indicators of irreversible lung function decline, as well as uncontrolled Type 2 inflammation, could reflect airway structural changes.

Company: Sanofi Genzyme & Regeneron


Sapphire Ballroom I/J/M/N (Sapphire Level, Level 4)

06:30 PM - 09:30 PM


Update on the Treatment of Sarcoidosis: Results of a Delphi Study

This interactive dinner symposium will present consensus findings from Delphi studies assessing the treatment of sarcoidosis and the current treatment patterns and management of repository corticotropin injection (RCI) for pulmonary sarcoidosis. We will also discuss the clinical phenotypes of sarcoidosis and the challenges of diagnosing and treating cardiac sarcoidosis. The objective is to increase the understanding and awareness of the current consensus on best practices among pulmonary sarcoidosis experts to improve patient outcomes. The format will be didactic presentations, moderator-driven Q&A, and panel discussions.

Speakers: Moderator: Daniel A. Culver DO Cleveland Clinic, Cleveland, OH; Robert P. Baughman MD University of Cincinnati Medical Center, Cincinnati, OH; Mary Beth Scholand MD University of Utah Medical Center, Salt Lake City, UT; Franck F. Rahaghi MD, MHS Cleveland Clinic Florida, Weston, FL; Edward J. Miller MD, PhD Yale University School of Medicine, New Haven, CT

Company: AXON Communications (supported by a medical eduction grant from Mallinckrodt Pharmaceuticals)


Manchester Grand Hyatt San Diego

Grand Hall A (Lobby Level)

06:30 PM - 09:30 PM


Treating Adults with Uncontrolled Severe Eosinophilic Asthma (SEA)

A review of considerations int he diagnosis and management of eosinophilic asthma.

Speakers: Mario Castro MD, MPH, FCCP ; Warner W. Carr MD, FAAAAI, FACAAI, FACP

Company: Teva


Grand Hall D (Lobby Level)

06:30 PM - 09:30 PM


The Future of Pneumonia Diagnostics: How Multiplex PCR will Change Patient Management

The complex microbiology of lower respiratory samples has thwarted attempts to develop broad molecular diagnostic panels in this area. BioFire has developed a test (currently IUO) which will identify 18 bacteria, 9 viruses, and 7 genetic markers of resistance in commonly collected lower respiratory specimens all in one hour. This symposium will feature Dr. Buchan and Dr. Stromich from the Medical College of Wisconsin, a clinical trial site for the BioFire Pneumonia Panel. Dr. Stormich will present patient cases from the clinical trial and discuss which patient populations will benefit most from the panel. Dr. Buchan will present an analysis exploring how frequently a pneumonia panel result can effectively tailor antimicrobial therapy.

Speakers: Blake Buchan PhD Medical College of Wisconsin; Jeremiah Stromich MD Medical College of Wisconsin

Company: BioFire Diagnostics


Seaport Ballroom G-H (Second Level, Seaport Tower)

06:30 PM - 09:30 PM


Exploring Eosinophilic Granulomatosis with Polyangiitis (EGPA): A Rare Disease

Eosinophilic Granulomatosis with Polyangiitis (EGPA), formerly known as Churg-Strauss syndrome, is a rare vasculitis that often involves the respiratory tract, affects small to medium vessels, and is associated with asthma and eosinophilia. EGPA is difficult to diagnose and manage due to its rarity and complexity. Early recognition is critical to avoid organ damage. This educational session will review the pathogenesis, clinical manifestations, classification criteria, diagnosis and prognosis of EGPA.

Speaker: Michael Wechsler MD, MMSc

Company: GlaxoSmithKline